title: Anticonvulsant-induced suppression of IFN-gamma production by lymphocytes obtained from cervical lymph nodes in glioma-bearing mice.
abstract: It is well known that phenytoin can cause impairment of cellular immunity. The authors investigated the potential role of other anticonvulsant drugs in the development of antitumor immunity in murine malignant glioma models. The survival rate was determined in murine glioma models using syngeneic 203 glioma cells following treatment with four anticonvulsants, which are most commonly administered to glioma patients, i.e., phenytoin, phenobarbital, valproate and zonisamide. In a second set of experiments, we further examined the effect of these drugs on interferon-gamma (IFN-gamma) secretion by lymphocytes prepared from cervical lymph nodes (CLN) in the same models. The IFN-gamma production of CLN lymphocytes as measured by ELISA method was markedly impaired in the early stage of tumor-bearing mice treated with phenytoin or zonisamide, and the median survival time (MST) of controls and of mice treated with either phenytoin or zonisamide was 13, 10 and 11 days, respectively, which was not a statistically significant difference. Phenobarbital and valproate did not affect either IFN-gamma production or their survival rate. In addition, immunohistochemistry showed a reduction in tumor-infiltrating lymphocytes containing CD4 and CD8 antigens in the mice treated with phenytoin and zonisamide. Two anticonvulsants, phenytoin and zonisamide, showed a significant inhibitory effect on IFN-gamma production by CLN lymphocytes in murine glioma models, although there was no statistically significant difference in MST between controls and the anticonvulsant-treated mice. These drugs might have some detrimental influence on the prognosis of brain tumor patients when combined with the latent immune dysfunction accompanying the tumor-bearing state.
authors.affiliation: Department of Neurosurgery, Osaka University Medical School, Suita City, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yamada
authors.forename: M
authors.initials: M
authors.lastname: Ohkawa
authors.forename: K
authors.initials: K
authors.lastname: Tamura
authors.forename: E
authors.initials: E
authors.lastname: Mabuchi
authors.forename: H
authors.initials: H
authors.lastname: Kishima
authors.forename: M
authors.initials: M
authors.lastname: Tamura
authors.forename: K
authors.initials: K
authors.lastname: Shimizu
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects*; D001921:Brain / Q000473:pathology; D001932:Brain Neoplasms / Q000276:immunology* / Q000473:pathology; D004195:Disease Models, Animal; D005910:Glioma / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D007371:Interferon-gamma / Q000096:biosynthesis* / Q000378:metabolism; D008198:Lymph Nodes / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009333:Neck; D010672:Phenytoin / Q000009:adverse effects*; D011379:Prognosis; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D000927:Anticonvulsants; D010672:Phenytoin; D007371:Interferon-gamma